•
Sep 30, 2021
Akero Q3 2021 Earnings Report
Akero Therapeutics reported financial results for the third quarter of 2021.
Key Takeaways
Akero Therapeutics reported third quarter financial results with focus on advancing efruxifermin (EFX) through Phase 2b clinical trials for NASH treatment.
Focused on completing two Phase 2b clinical trials.
Diligently working with regulators to bring efruxifermin (EFX) to market.
Received Fast Track designation from the FDA.
EFX is being evaluated in the HARMONY and SYMMETRY studies.
Akero
Akero
Forward Guidance
Forward-looking statements involve risks and uncertainties, and actual results may differ materially.